Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression profile of frizzled receptors in human medulloblastomas.
Salsano E, Paterra R, Figus M, Menghi F, Maderna E, Pollo B, Solero CL, Massimi L, Finocchiaro G. Salsano E, et al. Among authors: paterra r. J Neurooncol. 2012 Jan;106(2):271-80. doi: 10.1007/s11060-011-0682-6. Epub 2011 Aug 18. J Neurooncol. 2012. PMID: 21850537
FABP4 is a candidate marker of cerebellar liponeurocytomas.
Anghileri E, Eoli M, Paterra R, Ferroli P, Pollo B, Cuccarini V, Maderna E, Tringali G, Saini M, Salsano E, Finocchiaro G. Anghileri E, et al. Among authors: paterra r. J Neurooncol. 2012 Jul;108(3):513-9. doi: 10.1007/s11060-012-0853-0. Epub 2012 Apr 3. J Neurooncol. 2012. PMID: 22476608
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide.
Pellegatta S, Eoli M, Cuccarini V, Anghileri E, Pollo B, Pessina S, Frigerio S, Servida M, Cuppini L, Antozzi C, Cuzzubbo S, Corbetta C, Paterra R, Acerbi F, Ferroli P, DiMeco F, Fariselli L, Parati EA, Bruzzone MG, Finocchiaro G. Pellegatta S, et al. Among authors: paterra r. Oncoimmunology. 2018 Jan 29;7(4):e1412901. doi: 10.1080/2162402X.2017.1412901. eCollection 2018. Oncoimmunology. 2018. PMID: 29632727 Free PMC article.
In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
Cuccarini V, Antelmi L, Pollo B, Paterra R, Calatozzolo C, Nigri A, DiMeco F, Eoli M, Finocchiaro G, Brenna G, Tramacere I, Bruzzone MG, Anghileri E. Cuccarini V, et al. Among authors: paterra r. Neurol Sci. 2020 Feb;41(2):347-355. doi: 10.1007/s10072-019-04087-9. Epub 2019 Oct 24. Neurol Sci. 2020. PMID: 31650436
Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy.
Eoli M, Corbetta C, Anghileri E, Di Ianni N, Milani M, Cuccarini V, Musio S, Paterra R, Frigerio S, Nava S, Lisini D, Pessina S, Maddaloni L, Lombardi R, Tardini M, Ferroli P, DiMeco F, Bruzzone MG, Antozzi C, Pollo B, Finocchiaro G, Pellegatta S. Eoli M, et al. Among authors: paterra r. Neurooncol Adv. 2019 Aug 20;1(1):vdz022. doi: 10.1093/noajnl/vdz022. eCollection 2019 May-Dec. Neurooncol Adv. 2019. PMID: 32642658 Free PMC article.
High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Anghileri E, Di Ianni N, Paterra R, Langella T, Zhao J, Eoli M, Patanè M, Pollo B, Cuccarini V, Iavarone A, Rabadan R, Finocchiaro G, Pellegatta S. Anghileri E, et al. Among authors: paterra r. Cancer Immunol Immunother. 2021 Mar;70(3):831-842. doi: 10.1007/s00262-020-02769-4. Epub 2020 Nov 3. Cancer Immunol Immunother. 2021. PMID: 33140187 Free PMC article.
30 results